Genomic subtypes of cutaneous melanoma have distinct metabolic profiles: A single-cell transcriptomic analysis.

TitleGenomic subtypes of cutaneous melanoma have distinct metabolic profiles: A single-cell transcriptomic analysis.
Publication TypeJournal Article
Year of Publication2023
AuthorsDiaz MJ, Tran JT, Choo Z-N, Root KT, Batchu S, Milanovic S, Ladehoff L, Fadil A, Lipner SR
JournalArch Dermatol Res
Volume315
Issue10
Pagination2961-2965
Date Published2023 Dec
ISSN1432-069X
KeywordsGenomics, Humans, Melanoma, Melanoma, Cutaneous Malignant, Metabolome, Mutation, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Transcriptome
Abstract

OBJECTIVE: Genomic profiling previously classified melanoma into distinct subtypes based on the presence or absence of mutations in driver genes, but metabolic differences between and within these groups have yet to be thoroughly analyzed. Thus, the objective of the present study is to provide the first effort to holistically characterize the metabolic landscape of qualified melanoma genomic subtypes at single-cell resolution.

METHODS: Expression data for a total of 1145 malignant cells sourced from NRAS(Q61L), BRAF(V600E), and NRAS/BRAF WT melanomas were retrieved from the Broad Single Cell Portal. Metabolic activity was interrogated by pathway scoring and gene set enrichment analysis.

RESULTS: A total of 53 metabolic pathways were differentially regulated in at least one melanoma genomic subtype. Some notable findings include: BRAF/NRAS WT cells were enriched for fatty acid biosynthesis and depleted for metabolism of alanine, aspartate, and glutamate; BRAF(V600E) melanoma cells were enriched for beta-alanine metabolism and depleted for phenylalanine metabolism; NRAS(Q61L) melanoma cells were enriched for steroid biosynthesis and depleted for linoleic acid metabolism.

CONCLUSION: Primary limitations include the total quantity of single cells and breadth of available genomic subtypes plus inherent noisiness of the applied methodologies. Nonetheless, these findings nominate novel, testable therapeutic targets.

DOI10.1007/s00403-023-02690-7
Alternate JournalArch Dermatol Res
PubMed ID37658915
PubMed Central ID5993208

Person Type: